As predicted, the addition of ICB with CDK4/6 and PI3Kalpha inhibitors enhances anti-tumor immune responses, further supporting the concept that combinatorial approaches targeting both the cell cycle and pathways that augment T-cell function are synergistic58. This evidence concerns the gene CDK4 and neoplasm.